These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19111162)

  • 1. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes.
    You S; Candon S; Kuhn C; Bach JF; Chatenoud L
    Adv Immunol; 2008; 100():13-37. PubMed ID: 19111162
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune intervention with anti-CD3 in diabetes.
    Harlan DM; von Herrath M
    Nat Med; 2005 Jul; 11(7):716-8. PubMed ID: 16015359
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
    Chatenoud L
    Handb Exp Pharmacol; 2008; (181):221-36. PubMed ID: 18071948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD3-specific antibodies: a portal to the treatment of autoimmunity.
    Chatenoud L; Bluestone JA
    Nat Rev Immunol; 2007 Aug; 7(8):622-32. PubMed ID: 17641665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications.
    Chatenoud L
    Curr Opin Immunol; 2005 Dec; 17(6):632-7. PubMed ID: 16214320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].
    Chatenoud L
    Med Sci (Paris); 2006 Jan; 22(1):5-6. PubMed ID: 16386207
    [No Abstract]   [Full Text] [Related]  

  • 7. CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic.
    Chatenoud L
    Int Rev Immunol; 2006; 25(3-4):215-33. PubMed ID: 16818372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing viral-induced type 1 diabetes.
    Richer MJ; Horwitz MS
    Ann N Y Acad Sci; 2009 Sep; 1173():487-92. PubMed ID: 19758190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling type 1 diabetes: new immune-modulating drugs attack the root cause.
    Shekhar C
    Chem Biol; 2007 Dec; 14(12):1305-6. PubMed ID: 18096495
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.
    Sasaki N; Yamashita T; Takeda M; Shinohara M; Nakajima K; Tawa H; Usui T; Hirata K
    Circulation; 2009 Nov; 120(20):1996-2005. PubMed ID: 19884470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.
    Ochi H; Abraham M; Ishikawa H; Frenkel D; Yang K; Basso A; Wu H; Chen ML; Gandhi R; Miller A; Maron R; Weiner HL
    J Neurol Sci; 2008 Nov; 274(1-2):9-12. PubMed ID: 18804221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-lymphocyte antibody-based immunotherapy in type 1 diabetes.
    Xia CQ; Liu YT; Guan QB; Clare-Salzler M
    Chin Med J (Engl); 2013 Mar; 126(5):957-64. PubMed ID: 23489809
    [No Abstract]   [Full Text] [Related]  

  • 13. New approaches to diabetes disease control, insulin delivery, and monitoring.
    McCarthy AA
    Chem Biol; 2004 Dec; 11(12):1597-8. PubMed ID: 15610839
    [No Abstract]   [Full Text] [Related]  

  • 14. Dysrulation of T cell peripheral tolerance in type 1 diabetes.
    Tisch R; Wang B
    Adv Immunol; 2008; 100():125-49. PubMed ID: 19111165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New prospects for immunotherapy at diagnosis of type 1 diabetes.
    Pozzilli P; Leslie RD
    Diabetes Metab Res Rev; 2009 May; 25(4):299-301. PubMed ID: 19405079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The little antibody that could.
    Gorman C
    Time; 2002 Jun; 159(23):69. PubMed ID: 12066498
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage.
    Waldron-Lynch F; Herold KC
    Endocrinol Metab Clin North Am; 2009 Jun; 38(2):303-17, viii. PubMed ID: 19328413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of residual beta cells and islet autoimmunity during increasing duration of diabetes in NOD mice and experimental approaches toward reversing new-onset disease with bioactive peptides.
    Reddy S; Cheung CC; Chai RC; Rodrigues JA
    Ann N Y Acad Sci; 2008 Dec; 1150():171-6. PubMed ID: 19120289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of vitamin D receptor gene polymorphisms FokI and BsmI in Brazilian individuals with type 1 diabetes and their relation to beta-cell autoimmunity and to remaining beta-cell function.
    Mory DB; Rocco ER; Miranda WL; Kasamatsu T; Crispim F; Dib SA
    Hum Immunol; 2009 Jun; 70(6):447-51. PubMed ID: 19286443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of innate immune responses in autoimmune disease development.
    Waldner H
    Autoimmun Rev; 2009 Mar; 8(5):400-4. PubMed ID: 19162250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.